

# Formulary quarterly impact report

State of New Mexico RMD

Formulary type: Standard with ACSF

Claims Period: June 2023 - September 2023



This report contains confidential and proprietary information of CVS Health and cannot be reproduced, distributed or reprinted without permission from CVS Health. Every effort is made by CVS Caremark and its advisors to maintain the highest level of accuracy in its projections; however, because of the variability of a number of factors, which are not under the control of CVS Caremark, we cannot guarantee the estimated results shown. Tier values of "X" indicate the drug is not part of CVS Caremark's standard formulary. Drug may be subject to PA/medical exceptions process or no drug coverage. ©2023 CVS Health and/or one of its affiliates: Confidential & Proprietary

# Formulary quarterly impact report

## Current utilization summary

Distinct Utilizers	Rxs	Days	Gross	Net
31,525	233,874	7,408,496	\$36,533,958	\$34,017,633

## Estimated impact of formulary update

Change category	Member impact	Distinct utilizers impacted*	Percent (%) total utilizing members impacted	Impacted Rxs	Percent (%) total Rxs impacted
Exclusion	Positive	6	0.02%	17	0.01%
Exclusion	Negative	932	2.96%	1,740	0.74%
<b>Exclusion</b>	<b>Total</b>	<b>938</b>	<b>2.98%</b>	<b>1,757</b>	<b>0.75%</b>
Tier change	Positive	28	0.09%	43	0.02%
Tier change	Negative	27	0.09%	42	0.02%
<b>Tier change</b>	<b>Total</b>	<b>55</b>	<b>0.17%</b>	<b>85</b>	<b>0.04%</b>
<b>Total</b>		<b>988</b>	<b>3.13%</b>	<b>1,842</b>	<b>0.79%</b>

\*The sum of distinct utilizers is greater than the Total Impacted Distinct Utilizers due to overlap among positively impacted and negatively impacted products.

Also see disclaimer notes on cover page.  
©2023 CVS Health and/or one of its affiliates: Confidential & Proprietary



# Formulary quarterly impact report - drug detail

## Formulary impact - drug detail

Drug name	Therapeutic class	Change category	Member impact	Current tier	New tier	Utilizers	Rxs	Current gross cost	Current member cost	Current net cost
BASAGLAR KWK	INSULIN	Exclusion	Negative	2	X	295	658	\$248,953	\$18,025	\$230,928
EPINEPH(E)2P	ANAPHYLAXIS THERAPY AGENTS	Exclusion	Negative	1	X	236	262	\$82,116	\$1,614	\$80,502
SYMBICORT	SYMPATHOMIMETICS	Exclusion	Negative	2	X	194	340	\$172,845	\$36,013	\$136,832
LEVEMIR FLEX	INSULIN	Exclusion	Negative	2	X	102	207	\$143,398	\$6,361	\$137,037
ADVAIR HFA	SYMPATHOMIMETICS	Exclusion	Negative	2	X	44	67	\$35,838	\$7,075	\$28,763
LEVEMIR	INSULIN	Exclusion	Negative	2	X	24	49	\$31,069	\$1,511	\$29,558
OPZELURA	ECZEMA AGENTS	Tier Change	Positive	3	2	22	37	\$74,783	\$5,155	\$69,628
AIMOVIG	CALCITONIN GENE-RELATED PEPTIDE (CGRP) RECEPTOR ANT	Exclusion	Negative	2	X	20	64	\$45,140	\$5,687	\$39,453
AIMOVIG 1PK	CALCITONIN GENE-RELATED PEPTIDE (CGRP) RECEPTOR ANT	Exclusion	Negative	2	X	13	39	\$28,924	\$3,525	\$25,399
TRUEPLUS	DIABETIC SUPPLIES	Tier Change	Negative	2	3	9	15	\$76	\$76	\$0
GENOTROPIN	GROWTH HORMONES	Exclusion	Negative	2	X	5	18	\$95,198	\$517	\$94,681
EPIPEN 2-PAK	ANAPHYLAXIS THERAPY AGENTS	Exclusion	Negative	2	X	4	4	\$2,913	\$480	\$2,433
FREESTYLE	DIABETIC SUPPLIES	Tier Change	Negative	2	3	4	4	\$31	\$31	\$0
MICROLET	DIABETIC SUPPLIES	Tier Change	Negative	2	3	4	6	\$84	\$84	\$0
AMJEVITA	ANTI-TNF-ALPHA - MONOCLONAL ANTIBODIES	Exclusion	Negative	3	X	3	6	\$28,174	\$0	\$28,174
ACCU-CHEK	DIABETIC SUPPLIES	Tier Change	Positive	3	2	2	2	\$13	\$6	\$6
ARAZLO	ACNE PRODUCTS	Exclusion	Negative	2	X	2	4	\$1,987	\$480	\$1,507
BESREMI	ANTINEOPLASTICS MISC.	Tier Change	Positive	3	2	2	2	\$28,755	\$0	\$28,755
DULERA	SYMPATHOMIMETICS	Exclusion	Positive	X	3	2	8	\$2,621	\$1,240	\$1,381
EYLEA	OPHTHALMIC - ANGIOGENESIS INHIBITORS	Exclusion	Negative	2	X	2	4	\$7,348	\$0	\$7,348
JAKAFI	ANTINEOPLASTIC ENZYME INHIBITORS	Exclusion	Negative	3	X	2	7	\$115,948	\$14,601	\$101,347
LANCET ULTRA	DIABETIC SUPPLIES	Tier Change	Negative	2	3	2	2	\$19	\$7	\$13
MULTAQ	ANTIARRHYTHMICS TYPE III	Exclusion	Positive	X	2	2	5	\$4,972	\$741	\$4,231
PREZCOBIX	ANTIRETROVIRALS	Tier Change	Negative	2	3	2	8	\$18,313	\$760	\$17,553
RHOFADE	ROSACEA AGENTS	Tier Change	Negative	2	3	2	2	\$1,085	\$190	\$895
XTAMPZA ER	OPIOID AGONISTS	Exclusion	Negative	2	X	2	6	\$2,706	\$380	\$2,326
AVSOLA	INFLAMMATORY BOWEL AGENTS	Exclusion	Positive	X	2	1	1	\$1,420	\$0	\$1,420
GONAL-F	FERTILITY REGULATORS	Exclusion	Negative	2	X	1	2	\$8,712	\$0	\$8,712
LANCETS	DIABETIC SUPPLIES	Tier Change	Negative	2	3	1	1	\$9	\$9	\$0
LANCETS MICR	DIABETIC SUPPLIES	Tier Change	Negative	2	3	1	1	\$7	\$7	\$0
LANCETS SUPR	DIABETIC SUPPLIES	Tier Change	Negative	2	3	1	2	\$13	\$13	\$0

Also see disclaimer notes on cover page.

©2023 CVS Health and/or one of its affiliates: Confidential Proprietary



# Formulary quarterly impact report - drug detail

## Formulary impact - drug detail

Drug name	Therapeutic class	Change category	Member impact	Current tier	New tier	Utilizers	Rxs	Current gross cost	Current member cost	Current net cost
LANTUS SOLO	INSULIN	Exclusion	Positive	X	2	1	3	\$1,257	\$390	\$867
LUCENTIS	OPHTHALMIC - ANGIOGENESIS INHIBITORS	Exclusion	Negative	2	X	1	1	\$1,666	\$0	\$1,666
ONE TCH 30G	DIABETIC SUPPLIES	Tier Change	Positive	3	2	1	1	\$16	\$16	\$0
ONE TCH LANC	DIABETIC SUPPLIES	Tier Change	Positive	3	2	1	1	\$14	\$14	\$0
PREZISTA	ANTIRETROVIRALS	Exclusion	Negative	2	X	1	1	\$2,007	\$95	\$1,912
TECHLITE	DIABETIC SUPPLIES	Tier Change	Negative	2	3	1	1	\$2	\$2	\$0
TRIPTODUR	LHRH/GNRH AGONIST ANALOG PITUITARY SUPPRESSANTS	Exclusion	Negative	2	X	1	1	\$17,897	\$5,369	\$12,528